TriAltus Bioscience utilizes proprietary CLīM™ technology to produce ultra-pure genomic enzymes tailored for applications in enzymatic DNA synthesis and CRISPR. This platform addresses the need for high-quality enzyme supply in the life sciences sector, ensuring consistent performance and cost efficiency for biopharma companies.
Funding
Funding not disclosed
Founders
Product
Problem
Modern genomic applications, such as enzymatic DNA synthesis and CRISPR, demand extremely pure enzymes. Traditional purification methods often fall short, resulting in enzymes with insufficient purity, inconsistent performance, and high costs, hindering innovation and efficiency in biopharma research and development.
Solution
TriAltus Bioscience leverages its proprietary CLīM™ technology to produce ultra-pure genomic enzymes tailored for enzymatic DNA synthesis and CRISPR applications. The CLīM™ technology delivers enzymes with exceptional purity, superior activity, and consistent quality. As a CDMO and OEM supplier, TriAltus provides scalable production and customized formulations, streamlining the enzyme supply chain, reducing costs, and ensuring a dependable supply of high-quality enzymes.
Target Audience
The primary customers are biopharma companies and life science organizations involved in cutting-edge research and development, particularly in enzymatic DNA synthesis and CRISPR applications.
Features
- Proprietary CLīM™ technology for unparalleled enzyme purity
- Scalable production capabilities to meet growing demands
- Customizable enzyme formulations tailored to specific needs
- ISO13485:2016-compliant facilities ensuring consistent, high-quality production
- Specialization in genomic enzymes for CRISPR and enzymatic DNA synthesis
- CDMO services for custom enzyme solutions